Flemming Ornskov

Shire, the Irish rare diseases specialist that is a potential takeover target for Japan’s Takeda Pharmaceutical, is selling its oncology business to (...)

Shire, the Ireland-domiciled pharma group that specialises in rare diseases, has signed a training deal with the National Institute of Bioprocessing R(...)

Irish headquartered pharmaceutical company Shire said it was exploring options for its hyperactive drugs business, including a possible stock market l(...)

Earnings at Dublin-headquartered Shire Pharmaceuticals rose 14 per cent year on year during the first quarter of 2017 due to higher sales of rare dise(...)

Pharma giant Shire has received formal planning permission for its new $400 million (€371 million)biologics manufacturing facility on a 120 acre site (...)

Drugmaker Shire said the $32 billion takeover of US rival Baxalta will boost earnings and sales this year, sending its stock surging to the highest le(...)

Chief executives’ outsized pay packages are again coming under scrutiny, following a host of controversial pay awards in recent weeks. A fortnight ago(...)

Pharma group Shire is create 400 jobs in Co Meath over the next four years as part of a $400 million investment in the Republic. The company said it (...)

Flemming Ornskov had reason to be pleased yesterday. The Shire CEO’s six-month pursuit of rival Baxalta appears finally to have reached a successful c(...)

Dublin-based Shire has agreed to buy Dyax Corp for about $5.9 billion to gain access to the drug developer’s late-stage experimental treatment for a (...)